Credit Suisse has partnered up with Israel-based healthcare technology investment platform aMoon, the bank has announced.
Under the deal, the institutional investors and eligible clients of the bank and its asset management division will have access to the CHF 250 million aMoon II Venture Capital fund. Private investors in Israel had provisionally closed the aMoon II fund at USD 200 million on 1 April 2018.
The strategy is not available to clients in the US and Canada.
The fund invests in mid-to-late-stage health companies, with a focus on digital health, medical advices and biopharma. It supports underfunded and undervalued companies in global hubs that have strong healthcare technology ecosystems, such as in Israel, the US and Europe.
Michel Degen, CEO of Credit Suisse Asset Management Switzerland and EMEA, said: ‘It is critical that disruptive businesses, which are committed to resolving some of the healthcare sector’s most pressing issues, receive access to venture capital and the liquidity they need.
‘We are therefore delighted to enter into a strategic partnership with aMoon, a leader in health tech and life sciences investing.’